Next Article in Journal
Divergent Effects of Daidzein and Its Metabolites on Estrogen-Induced Survival of Breast Cancer Cells
Next Article in Special Issue
The Application of Deep Learning in Cancer Prognosis Prediction
Previous Article in Journal
Photochemical Internalization: Light Paves Way for New Cancer Chemotherapies and Vaccines
Previous Article in Special Issue
Parallel Structure Deep Neural Network Using CNN and RNN with an Attention Mechanism for Breast Cancer Histology Image Classification
Open AccessArticle

The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

1
Center for Personalized Cancer Therapy, University of California Moores Cancer Center, La Jolla, CA 92093, USA
2
CureMatch Inc., San Diego, CA 92121, USA
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(1), 166; https://doi.org/10.3390/cancers12010166
Received: 26 November 2019 / Revised: 21 December 2019 / Accepted: 7 January 2020 / Published: 9 January 2020
(This article belongs to the Collection Application of Bioinformatics in Cancers)
Metastatic cancer is a medical challenge that has been historically resistant to treatments. One area of leverage in cancer care is the development of molecularly-driven combination therapies, offering the possibility to overcome resistance. The selection of optimized treatments based on the complex molecular features of a patient’s tumor may be rendered easier by using a computer-assisted program. We used the PreciGENE® platform that uses multi-pathway molecular analysis to identify personalized therapeutic options. These options are ranked using a predictive score reflecting the degree to which a therapy or combination of therapies matches the patient’s biomarker profile. We searched PubMed from February 2010 to June 2017 for all patients described as exceptional responders who also had molecular data available. Altogether, 70 patients with cancer who had received 202 different treatment lines and who had responded (stable disease ≥12 months/partial or complete remission) to ≥1 regimen were curated. We demonstrate that an algorithm reflecting the degree to which patients were matched to the drugs administered correctly ranked the response to the regimens with a sensitivity of 84% and a specificity of 77%. The difference in matching score between successful and unsuccessful treatment lines was significant (median, 65% versus 0%, p-value <0.0001). View Full-Text
Keywords: precision medicine; neoplasms; molecular pathology; exceptional responders; therapeutic decision precision medicine; neoplasms; molecular pathology; exceptional responders; therapeutic decision
Show Figures

Figure 1

MDPI and ACS Style

Boichard, A.; Richard, S.B.; Kurzrock, R. The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments. Cancers 2020, 12, 166.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop